Pratt Collard Advisory Partners’s West Pharmaceutical WST Stock Holding History

Pratt Collard Advisory Partners’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$246K	Buy	+685	New	+$226K	0.16%	93

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Pratt Collard Advisory Partners's WST Position: Q2 2021 in Review

Pratt Collard Advisory Partners opened a new position in West Pharmaceutical (WST) in Q2 2021: 685 shares worth $246K. The stake represents 0.16% of the portfolio and ranks #93 among its holdings.

640 funds tracked by Wall St. Rank hold WST as of Q2 2021.

Pratt Collard Advisory Partners held 685 shares of West Pharmaceutical worth $246K as of Q2 2021.
West Pharmaceutical was a new Pratt Collard Advisory Partners position in Q2 2021.
West Pharmaceutical made up 0.16% of Pratt Collard Advisory Partners's portfolio in Q2 2021, its #93 holding.
640 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2021.

Based on Pratt Collard Advisory Partners's 13F filing for Q2 2021, filed 14 Jul 2021.